Metropolis Healthcare Ltd. has launched its Centre of Genomics to scale precision diagnostics and research in India. The centre will leverage Illumina’s NovaSeq™ X Series to enhance genomic research and expand access to advanced insights. Backed by two CAP-accredited genomics labs, the centre supports oncology, reproductive health, neurology, and rare diseases. Metropolis also plans to expand its genomic test portfolio to over 500+ advanced tests.
Centre of Genomics Launch
Metropolis Healthcare Limited announced the launch of its Centre of Genomics, designed to deliver clinically actionable genomic insights across various clinical specialties. The centre marks a significant step in scaling its capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research.
Technology and Capabilities
The Centre of Genomics is equipped with Illumina’s NovaSeq™ X Series to augment its existing sequencing infrastructure. The NovaSeq™ X Plus can generate more than 20,000 whole genomes per year, significantly increasing throughput and accuracy.
Focus Areas and Expansion
The centre supports key areas including oncology, reproductive health, neurology, transplant immunology, and rare diseases. Metropolis plans to expand its genomic portfolio to over 500+ advanced tests across key clinical specialties.
Expertise and Team
The Centre of Genomics brings together multidisciplinary teams including molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors.
Statements
Ms. Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare Limited, stated that genomics marks a decisive inflection point for diagnostics in India, expanding the role of laboratories to risk prediction, therapy personalization, and long-term disease management.
Source: BSE
